Yan-Rou Tsai, Dong Seok Kim, Shih-Chang Hsueh, Kai-Yun Chen, John Chung-Che Wu, Jia-Yi Wang, Yi-Syue Tsou, Inho Hwang, Yukyung Kim, Dayeon Gil, Eui Jung Jo, Baek-Soo Han, David Tweedie, Daniela Lecca, Michael T Scerba, Warren R Selman, Barry J Hoffer, Nigel H Greig, Yung-Hsiao Chiang
( 1 ) Background: An important concomitant of stroke is neuroinflammation. Pomalidomide, a clinically available immunomodulatory imide drug (IMiD) used in cancer therapy, lowers TNF-α generation and thus has potent anti-inflammatory actions. Well-tolerated analogs may provide a stroke treatment and allow evaluation of the role of neuroinflammation in the ischemic brain. ( 2 ) Methods: Two novel pomalidomide derivatives, 3,6'-dithiopomalidomide (3,6'-DP) and 1,6'-dithiopomalidomide (1,6'-DP), were evaluated alongside pomalidomide in a rat middle cerebral artery occlusion (MCAo) stroke model, and their anti-inflammatory actions were characterized...
April 27, 2022: Pharmaceutics